CBIO
Crescent Biopharma Inc (CBIO)
Healthcare • NASDAQ • $18.76+4.22%
- Symbol
- CBIO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $18.76
- Daily Change
- +4.22%
- Market Cap
- $517.30M
- Trailing P/E
- N/A
- Forward P/E
- -6.37
- 52W High
- $28.00
- 52W Low
- $8.72
- Analyst Target
- $29.43
- Dividend Yield
- N/A
- Beta
- N/A
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Company websiteResearch CBIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.